Progress of drug resistance mechanisms in acute promyelocytic leukemia / 白血病·淋巴瘤

ABSTRACT

Since all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) have become front-line drugs in treatment of acute promyelocytic leukemia (APL), cure rates of APL patients have improved dramatically. However, resistance to ATRA and/or As2O3has been a critical problem which has hampered the effect of treatment. In this review, some emerging mechanisms of resistance to ATRA and/or As2O3in recent years, such as genetic mutations, disorders of cellular signal transduction, disorders of chromatin remodeling complex, abnormal regulation of cell apoptosis, and micro-environment mediated drug resistance are summarized.